Tetulomab tetraxetan Lu-177

DB12227InvestigationalSmall molecule

Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.

Mechanism: Pharmacologically active on Leukocyte antigen CD37
Curator reviewed
Formula / weight: C₃₀H₄₇N₇O₁₀S · 697.81 g/mol (avg)
Also known as: 177Lu-tetraxetan-tetulomab · 177Lu-tetulomab · Anti-CD37 antibody tetulomab tetraxetan Lu-177 · Betalutin

Resolves to

Compound

Structure

InChIKeyRMJFCRKHOJOLIN-CGAIIQECSA-NSMILESN[C@@H](CCCCNC(=S)NC1=CC=C(CC2CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN2CC(O)=O)C=C1)C(O)=O

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Tetulomab tetraxetan Lu-177, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.